Just days after AstraZeneca PLC and FibroGen Inc. announced the first approval of the first-in-class anemia therapy, roxadustat, AstraZeneca has released top-line data from two Phase III clinical studies, OLYMPUS and ROCKIES, and FibroGen has released top-line data from three Phase III studies, ANDES, HIMALAYAS and SIERRAS, all showing that their primary endpoints were met.
AZ/FibroGen's Roxadustat Superior To Epoetin-Alfa In Chronic Renal Disease With Anemia
Positive top-line Phase III data from five studies, including the finding of superior efficacy to epotin-alfa, puts roxadustat in the driving seat as a new class of anemia agents heads toward the marketplace, but cardiovascular safety needs confirming.
More from Genitourinary
• By
Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.
• By
Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.
• By
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
• By
The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus